WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
A Guide to Patient Engagement & Recruitment Solutions
March 18th 2025Clinical trials have become increasingly complex over the past decades, making participant recruitment more challenging than ever. This guide explores common recruitment obstacles and offers strategies to overcome them using a patient engagement and recruitment solution.
Merits of a Multifaceted Approach to Clinical Trial Recruitment
March 18th 2025According to a 2024 study “Benchmarking Site Activation and Patient Enrollment,” 33% of sites under-enrolled, and 14% failed to enroll a single patient. The best way to course-correct this is to adopt a multifaceted approach to patient recruitment, that goes beyond traditional channels and ways of thinking.
Bridging the Gap: How Chiesi Used External Collaboration to Get Closer to Patients
March 18th 2025Chiesi partnered with Citeline to enhance clinical trial awareness and patient engagement through its FREUD initiative by launching a Trial Portfolio Website, activating 150+ sites, and generating 600+ qualified referrals—learn more about how Citeline helped improve study discoverability, streamline recruitment, and strengthen Chiesi’s presence in key therapeutic areas.
Citeline Patient Engagement & Recruitment Solutions
March 18th 2025Watch Citeline’s 15-minute presentation from Clinical Leader’s Patient Engagement & Recruitment Solutions Expo, where VP Matt Holms explores Direct-to-Data (DTD) patient recruitment. This session takes a deep dive into how complex algorithms, tokenized data, and large data assets can optimize enrollment, highlighting the importance of early strategic recruitment planning and breaking down the unique benefits and real-world applications of DTD.
Making the Grade: Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
February 13th 2025Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific, discusses the critical role of protocol-driven registries in generating regulatory grade RWE to serve multiple and evolving evidence needs across the drug development life cycle. He covers key considerations for selecting the right type of registry, explains why registry data is the gold standard in RWD, and how it contextualizes safety and effectiveness to fulfill FDA and EMA post-marketing requirements.
